You need the Flash Player version 8.0.0.0 or higher and a JavaScript enabled browser to view this content

Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: ASX
Sector: Aerospace
Epic: HTX
News: Latest news
Web Site: Healthlinx Limited
Other Articles: 24-02-201017-02-201005-02-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Saturday September 04, 06:00Serving up support at Babcock

Support services have been among the worst performing sectors over the past month as revenue fears from the government’s austerity measures weigh heavily on the sector.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday September 03, 11:40 Goldcorp snatches Andean Resources in $3.6bn deal, trumping Eldorado`s earlier bid

Both companies are vying for Andean`s Cerro Negro gold project, which is an advanced-stage, high-grade vein system, comprising 215 square kilometers. It currently has indicated resources of 2.54 million ounces of gold and 23.56 million ounces of silver, while inferred resources total 523,000 ounces of gold and 3.12 million ounces of silver.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 10:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Healthlinx Limited

Healthlinx Limited

Healthlinx Limited (ASX: HTX) is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms.  The company develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™.

 

Wednesday, December 02, 2009

HealthLinx opens up key UK market for its OvPlex™ Ovarian Cancer Diagnostic

company news image

Victorian-based diagnostics company HealthLinx (ASX: HTX) has taken a big step forward forging a key second market for its ovarian cancer diagnostic OvPlex™ in the UK.

The market responded to the announcement, pushing the HelathLinx share price up 17.6%, to $0.10.

United Kingdom Distributor Intus Healthcare has completed a commercial arrangement with major hospital and healthcare services group Spire Healthcare to process and market OvPlex™ in the UK from February 2010.

Market potential for OvPlex™ in the UK is greater than 750,000 units.

In a statement, the company said OvPlex™ is the most accurate commercially-available ovarian cancer diagnostic. The diagnostic is based on a simple blood test that women can request from their doctors." The launch in the UK is the first time the OvPlex™ diagnostic will be available outside Australia.

Nick Gatsios managing director of HelathLinx said “This is the next step in the global roll-out of OvPlex™ and we are confident that OvPlex™ is a best in market ovarian cancer diagnostic, as are our distribution partners. "

The company continues to deliver on its milestones and we believe commercial markets will respond positively to this latest achievement” says Mr Nick Gatsios, Managing Director of HealthLinx.

Spire Healthcare is the second largest private hospital group in the UK, with a network of 36 hospitals nationwide.

The group offers a range of services including pathology, diagnostic tests and investigations as well as the latest surgical procedures. The OvPlex™ test will be made available through its hospitals throughout England, Scotland and Wales.

Worldwide over 240,000 new cases of ovarian cancer are diagnosed each year while more than 130,000 women die from the disease. The UK region accounts for over 7,000 of these diagnoses and 4,000 lives lost every year.

Meanwhile, HealthLinx is continuing research and development on its next generation ovarian cancer diagnostic to further improve accuracy and earlier detection.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other Healthlinx Limited articles


Other Healthlinx Limited news

More news ►

Investors interested in Healthlinx Limited recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.